Browse RAET1E

Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 4: Secreted.
Domain PF00129 Class I Histocompatibility antigen
Function

Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity.

> Gene Ontology
 
Biological Process GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002250 adaptive immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0019882 antigen processing and presentation
GO:0042267 natural killer cell mediated cytotoxicity
Molecular Function GO:0003823 antigen binding
GO:0046703 natural killer cell lectin-like receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RAET1E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RAET1E and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16891318GlioblastomaPromote immunityWe further delineate two independent mechanisms that can explain these expression patterns: (i) transforming growth factor-beta (TGF-beta) is upregulated during malignant progression and selectively downregulates MICA, ULBP2 and ULBP4 expression, while MICB, ULBP1 and ULBP3 are unaffected. (ii) Cleavage of MICA and ULBP2 is reduced by inhibition of metalloproteinases (MP), whereas no changes in the expression levels of other NKG2DL were detected. Consequently, NKG2DL-dependent NK cell-mediated lysis is enhanced by depletion of TGF-beta or inhibition of MP.
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RAET1E in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RAET1E in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2990.507
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0630.932
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4820.471
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2690.614
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.840.522
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4690.709
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3370.649
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6060.643
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0640.964
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1890.727
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0190.981
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0520.868
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RAET1E in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAET1E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAET1E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAET1E.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAET1E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RAET1E expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RAET1E and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRAET1E
Nameretinoic acid early transcript 1E
Aliases LETAL; bA350J20.7; ULBP4; N2DL-4; NKG2DL42; RL-4; RAE-1-like transcript 4; lymphocyte effector toxicity acti ......
Chromosomal Location6q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RAET1E collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.